Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company developing treatments for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough depression? drug trial targets Non-Responders Results expected Aug 2027 (estimated)
-
Hope for lewy body dementia psychosis: new drug enters final testing phase
Disease control By invitation onlyThis study tests a drug called ACP-204 for treating psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a 52-week open-label extension, meaning all 126 participants will receive the drug. The main goal is to check for side effects over the long term. …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for Alzheimer's psychosis: ACP-204 safety trial expands
Symptom relief By invitation onlyThis study tests the long-term safety of a drug called ACP-204 for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). It lasts 52 weeks and includes 752 adults aged 55 to 95 who already completed a previous study of the same drug. The main goal…
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New nasal spray aims to tame relentless hunger in rare genetic disorder
Symptom relief OngoingThis Phase 3 trial tests a nasal spray called carbetocin to reduce the intense, constant hunger (hyperphagia) in people with Prader-Willi syndrome. The study involves 170 participants aged 5 to 30 and lasts 12 weeks. Caregivers will rate changes in hunger-related behaviors using …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 16:16 UTC